Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 80% Improvement Relative Risk Hospitalization time -75% Time to discharge -40% c19early.org/a Alosaimi et al. Favipiravir for COVID-19 LATE Favors favipiravir Favors HCQ
Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir
Alosaimi et al., Pharmaceuticals, doi:10.3390/ph15121456
Alosaimi et al., Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving.., Pharmaceuticals, doi:10.3390/ph15121456
Nov 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 200 hospitalized COVID-19 patients in Saudi Arabia, showing no significant difference in outcomes between HCQ and favipiravir.
risk of death, 80.0% lower, RR 0.20, p = 0.49, treatment 0 of 37 (0.0%), control 2 of 37 (5.4%), NNT 18, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), propensity score matching.
hospitalization time, 75.0% higher, relative time 1.75, p = 0.63, treatment 37, control 37, propensity score matching.
time to discharge, 40.0% higher, relative time 1.40, p = 0.74, treatment 37, control 37, propensity score matching.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Alosaimi et al., 24 Nov 2022, retrospective, Saudi Arabia, peer-reviewed, 13 authors, study period April 2020 - March 2021, this trial compares with another treatment - results may be better when compared to placebo.
Contact: w.alturaiki@mu.edu.sa (corresponding author).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Abstract: pharmaceuticals Article Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir Bandar Alosaimi 1 , Huda M. Alshanbari 2 , Muath Alturaiqy 3 , Halah Z. AlRawi 1 , Saad Alamri 1 , Asma Albujaidy 4 , Aljawharah Bin Sabaan 5 , Ahmed A. Alrashed 6 , Ahmad Alamer 7,8 , Fayez Alghofaili 9 , Khaled Al-Duraymih 10 , Abdulaziz J. Alshalani 11 and Wael Alturaiki 9, * 1 2 3 4 5 6 7 8 9 Citation: Alosaimi, B.; Alshanbari, 10 H.M.; Alturaiqy, M.; AlRawi, H.Z.; Alamri, S.; Albujaidy, A.; Bin Sabaan, A.; Alrashed, A.A.; Alamer, A.; 11 * Research Center, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh 11525, Saudi Arabia Department of Mathematical Sciences, College of Science, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia Department of Internal Medicine, Alzulfi General Hospital, Riyadh Second Health Cluster, Riyadh 11525, Saudi Arabia Department of Clinical Pharmacy Service, Prince Mohammed bin Abdulaziz Hospital, Riyadh Second Health Cluster, Riyadh 11525, Saudi Arabia Pharmacy College, Almaarifa University, Riyadh 11597, Saudi Arabia Department of Pharmaceutical Services, Main Hospital, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh 11525, Saudi Arabia Department of Clinical Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj 11942, Saudi Arabia Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Majmaah University, Majmaah 11952, Saudi Arabia Main Laboratory and Blood Bank, Alzulfi General Hospital, Riyadh Second Health Cluster, Riyadh 11525, Saudi Arabia Alzulfi General Hospital, Riyadh Second Health Cluster, Riyadh 11525, Saudi Arabia Correspondence: w.alturaiki@mu.edu.sa Alghofaili, F.; et al. Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir. Pharmaceuticals 2022, 15, 1456. https://doi.org/10.3390/ph15121456 Academic Editor: Marco Fiore Received: 14 October 2022 Accepted: 18 November 2022 Published: 24 November 2022 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ Abstract: Background: The coronavirus 2019 (COVID-19) disease, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus led to a global pandemic. HCQ and FPV were used early in the pandemic as a treatment modality for COVID-19. Various studies evaluated the HCQ and FPV effectiveness, based on the mortality endpoint and showed conflicting results. We hypothesize that analyzing the difference in the LOS as a significant endpoint would be of a major interest, especially for healthcare providers, to prevent a lengthy hospitalization and disease progression. Methods: This is a retrospective observational study, conducted via a medical chart review of COVD-19 patients who were admitted between April 2020 and March 2021 with a moderate to severe illness. The LOS endpoint was tested using the paired Wilcoxon signed-rank (WSR) model. Prior to using the WSR model, the balance..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit